- Retatrutide 12 mg led to 28.7% weight loss at 68 weeks in TRIUMPH-4 trial.
- WOMAC pain scores reduced by 4.5 points, with improved physical function.
- 84% of participants had a baseline BMI of ≥35 kg/m².
- Seven more Phase 3 trials to complete in 2026.
Trial Results
The Phase 3 TRIUMPH-4 trial evaluated retatrutide, a triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis. Participants taking 12 mg of retatrutide lost an average of 28.7% of their body weight over 68 weeks. The trial also showed a reduction in WOMAC pain scores by an average of 4.5 points, equating to a 75.8% decrease in pain.
Participant Details
In this global registration trial, 84% of participants had a baseline BMI of ≥35 kg/m². The trial assessed the safety and efficacy of retatrutide as an adjunct to a healthy diet and physical activity, meeting all primary and key secondary endpoints.
Future Trials
Seven additional Phase 3 trials are planned to evaluate retatrutide for obesity and type 2 diabetes, with completion expected in 2026. These trials aim to further assess the treatment's potential benefits and expand its application to a broader patient population.
